Biopsy Devices Market - By Product Type, By End Use - Global Forecast 2025 - 2034

Biopsy Devices Market Size

The global biopsy devices market size was valued at USD 2.9 billion in 2024 and is expected to reach USD 5.3 billion in 2034, growing at a CAGR of 6% from 2025 to 2034. Biopsy devices are used to capture tissue samples from the human body for diagnosis, usually to confirm cancer, infection, or other pathological conditions. They comprise of instruments with needles, forceps, vacuum-assisted devices, and imaging-guided biopsy machinery.
 

Rising cancer cases across the globe is a major factor driving the growth of these devices as accurate diagnosis is crucial for effective treatment. Pathological evaluation of tissue specimens obtained through biopsies remains best methodology to confirm malignancy. Moreover, as the incidence of lung, colorectal, breast, and prostate cancers is increasing, healthcare providers are witnessing a rise in the volume of diagnostic procedures needing sophisticated biopsy techniques. For instance, the Global Cancer Observatory (GLOBOCAN) has estimated that there were 19,976,499 cases of cancer and 9,743,832 deaths due to the disease in the year 2022. This increasing burden of cancer also creates a demand for frequent biopsies to get more precise identification and understand the stage of the disease.
 

Additionally, early-stage breast cancer detection initiatives and awareness campaigns have increased the usage of breast biopsy devices, which is expected to reach 3.6 billion by 2032. Increased government and healthcare organisations’ efforts for creating awareness about this disease are positively influencing the number of biopsy procedures performed. For example, the Global Cancer Observatory states that breast cancer is the most widespread cancer globally, with 2.3 million new cases reported in 2022. Participation in screening programs and improvements in biopsy methods are expected to drive growth in this market.
 

 Biopsy Devices Market Trends

• Real-time imaging methods such as ultrasounds and CT scans are being used to increase accuracy and efficiency while performing biopsies. Newer technologies in image-guided biopsy are improving the precision in cancer detection at initial stages and the risks are also minimized. For instance, Hologic’s Brevera Breast Biopsy System which integrates tissue acquisition improves efficiency and diagnostic accuracy of surgical biopsies with real-time imaging.
   
• Moreover, robotic-assisted systems for biopsies improve efficiency and human errors while tissue sampling. These systems offer greater accuracy and the possibility of less invasive interventions which can speed up recovery time for patients. For instance, the Ion Endoluminal System by Intuitive Surgical is a robotic platform for performing minimally invasive lung biopsy procedures. This device gives full bronchial access which aids the physician to check deep into the lung with a flexible robotic catheter.
   
• Further, to reduce cross-contamination and hospital-acquired infection, healthcare professionals are moving towards single-use biopsy instruments. There is also increased focus on patient safety and infection control, which is driving regulatory guidelines. For example, Merit Medical incorporates a single-use design in the form of a compact, ergonomically contoured body, to improve procedural safety in its Temno Evolution Biopsy Device.
   
• Diagnostic surgery is progressively adopting artificial intelligence (AI) technology to facilitate the interpretation of pathology reports, decrease the diagnostic error rate, and speed up the processes involved in analyzing biopsy specimens. Evaluation and reporting of specimens are now being automated through AI-powered pathology systems which are transforming the efficacy of laboratory work. In September 2021 for example, Paige Prostate became the first AI-based pathology product to help with prostate cancer detection, receiving FDA approval. It uses clinical AI to increase accuracy while improving the speed of prostate biopsy diagnoses.
   

Biopsy Devices Market Analysis

Based on product type, the market is segmented into biopsy guidance systems, needle-based biopsy guns, biopsy needles, biopsy forceps and other product types. The global market was valued at USD 2.7 billion in 2023. The biopsy guidance systems segment dominated the market with the largest revenue of USD 1.2 billion in 2024.
 

• The biopsy guidance systems have real-time visualization combined with accurate targeting which makes them vital in performing precise and minimally invasive biopsies. They have become the preferred option in numerous diagnostic processes because of their capability to guide clinicians to small or difficult-to-access lesions.
   
• Additionally, the use of these systems has increased in hospitals and diagnostic centers due to advancements in ultrasound, CT, and MRI integration. Their multi-modality compatibility boosts clinical efficiency as well as optimized procedural outcomes.
   
• For example, Olympus Corporation provides the EZ Shot 3 Plus, an endoscopic ultrasound (EUS) needle which offers greater precision for tissue sampling.
   
• Furthermore, the segment is expected to maintain its dominance due to the high demand for accurate, image-guided diagnostics, the rising number of cancer cases, and continuous advancements that enhance clinical workflow, patient safety, and diagnostic yield.
   

Based on end use, the biopsy devices market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment emerged as a dominant segment in the market, accounting for 67.9% of revenue share in 2024 and is expected to reach USD 3.6 billion by 2034.
 

• The hospital segment was found to be dominating in comparison to other segments, as they are the primary settings for complex and high-volume biopsies performed in with most sophisticated imaging resources and skilled staff.
   
• This segment has profited from the increasing volume of hospitalizations due to cancer diagnostic procedures, chronic illnesses, and trauma patients needing image-guided biopsies for precise tissue sampling. The multidisciplinary cancer treatment centers in the hospitals further facilitate the growing use of biopsy devices.
   
• In addition, there is a greater adoption of minimally invasive and robotic-assisted biopsies performed at the hospitals, which improves precision, procedural time, and patient outcomes, resulting in further growth of the segment.
   

North America: The U.S. biopsy devices market revenue is expected to increase considerably from USD 451.9 million in 2023 to reach USD 808.9 million by 2034.
 

• The country has a high volume of cancer cases. The National Institutes of Health projects that 2,001,140 new cases of cancer alongside 611,720 cancer fatalities are projected to occur in the country in 2024.
   
• Moreover, the adoption of advanced imaging and inpatient and outpatient procedures is facilitated by a positive reimbursement policy in the U.S. The payment of Medicare and private insurers also enables the full market participation of image-guided and minimally invasive biopsies.
   

Europe: The UK biopsy devices market is projected to experience steady growth between 2025 and 2034.
 

• The country has marked an increasing demand for chronic ailments which is one of the factors for boosting this market in the UK.
   
• Based on information from Cancer Research UK, there are more than 55,000 new cases of breast cancer registered among women in the UK each year. The government initiatives aimed at timely screening and diagnosis of cancer have greatly enhanced the number of biopsies conducted.
   
• In addition, the NHS funds biopsies as part of defined cancer care pathways ensuring timely diagnosis and therefore increasing the use of biopsy devices, further fostering the market growth.
   

Asia Pacific: Japan biopsy devices market is poised to witness lucrative growth between 2025 - 2034.
 

• Japan's aging population is a major factor driving demand for biopsy devices. According to Statista, as of November 2023, 36.35 million people (29% of the population) were aged 65 or older. The elderly are more prone to chronic diseases, including cancer necessitating the use of effective diagnostic solutions.
   
• Moreover, awareness regarding the disease is increasing, further promoting the expansion of this market.
   

Middle East and Africa: The biopsy devices market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The country is also experiencing an aging population. For instance, the number of people aged sixty and above is projected to rise five-fold from 2 million (5.9% of the total population) in 2020, to 10.5 million by 2050.
   
• Furthermore, the increasing prevalence of cancer is among the key factors for supporting the market in Saudi Arabia. According to the data provided by the GLOBOCAN 2022, there were 28,113 new cases of cancer in Saudi Arabia along with 13,399 deaths in 2022. Such figures contribute to the growth of this market and the market is expected to surge in the coming years as well.
   

Biopsy Devices Market Share

The top 4 players including BD, Boston Scientific, Medtronic, and Hologic, have a significant share in the global market accounting for approximately 40% of the market, as a result of their continuous investment in advanced technologies, strategic acquisitions, integrated diagnostic solutions, and overall market development. On the other hand, mid-sized and emerging companies such as Argon Medical Devices, Armis Biopharma, INRAD, and Cook Group are intensifying market competition with their specialized, economical devices designed for niche applications. This evolving competitive environment fueled by increasing market demand for precision-guided, minimally invasive diagnostics and procedures is supporting the developing and developed healthcare markets’ acceptance of innovative biopsy solutions.
 

 Biopsy Devices Market Companies

Some of the eminent market participants operating in the biopsy devices industry include:

• Argon Medical Devices
• B. Braun Melsungen
• Becton, Dickinson, and Company
• Boston Scientific
• Cardinal Health
• Cook Group
• Devicor Medical Products
• FUJIFILM
• Hologic
• INRAD
• Medtronic
• Olympus Corporation
• Stryker Corporation
   
• BD has a diverse business portfolio and global presence in the surgical biopsy market. BD is present in over 190 countries and provides various types of biopsy needles and guidance systems used in hospitals, cancer centers, and diagnostic laboratories across the globe.
   
• Boston Scientific Corporation heavily specializes in minimally invasive therapeutics for oncology. Boston Scientific uses its interventional endoscopy knowledge to provide state-of-the-art biopsy instruments for lung and gastrointestinal cancers. For example, the Acquire EUS-FNB device provides one of the greatest tissue yields for pancreatic and gastrointestinal biopsies and is used globally.
   

Biopsy Devices Industry News:

• In January 2021, Hologic declared the acquisition of SOMATEX Medical Technologies GmbH, one of the leading players involved in the development of localization technologies and biopsy site markers. This acquisition has helped Hologic in expanding its product portfolio, thereby benefiting the company’s overall growth.
   
• In February 2024, Argon Medical, simultaneously announced their expansion of the liver management portfolio with the launch of Intara Introducer Sheath and TLAB Transvenous Liver Biopsy System products in the U.S. and Canada. With the introduction of the products, the company hopes to improve procedural efficiency and increase their scope under interventional oncology, further strengthening its position in market.
   
• In December 2020, Olympus Corporation announced the acquisition of Veran Medical Technologies, Inc. This strategic acquisition enhanced Olympus’s product portfolio of endo-therapy division.
   

The biopsy devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Biopsy guidance systems
  • Manual
  • Robotic 
• Needle based biopsy guns
  • Vacuum-assisted biopsy (VAB) devices
  • Fine needle aspiration biopsy (FNAB) devices
  • Core needle biopsy (CNB) devices
• Biopsy needles
  • Disposable
  • Reusable
• Biopsy forceps
  • General biopsy forceps
  • Hot biopsy forceps
• Other product types
  • Brushes
  • Curettes
  • Punches

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE